发明名称 |
Use of an isolated human anti-tnfa antibody in the manufacture of medicament for treating a disease selected from rheumatoid spondylitis and autoimmune uveitis, a pharmaceutical composition, a kit and a preloaded syringe comprising the same |
摘要 |
<p>Methods of treating disorders in which TNF± activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ± (hTNF ±) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF± (e.g., K d = 10 -8 M or less), a slow off rate for hTNF± dissociation (e.g., K off = 10 -3 sec -1 or less) and neutralize hTNF± activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.</p> |
申请公布号 |
IL212419(A) |
申请公布日期 |
2015.03.31 |
申请号 |
IL20110212419 |
申请日期 |
2011.04.17 |
申请人 |
ABBVIE BIOTECHNOLOGY LTD. |
发明人 |
|
分类号 |
A61K;A61M5/28;A61K31/519;A61K38/00;A61K39/395;A61M;A61P1/00;A61P1/16;A61P3/10;A61P7/04;A61P9/00;A61P9/10;A61P11/00;A61P13/12;A61P17/02;A61P19/02;A61P19/06;A61P19/08;A61P25/00;A61P27/02;A61P29/00;A61P31/00;A61P35/00;A61P37/02;A61P37/06;A61P37/08;C07K;C07K16/24 |
主分类号 |
A61K |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|